Although several studies have followed the course of depression throughout the lifespan, the characteristics of depression at different developmental stages haven't been clearly identified. New research published in Clinical Psychological Science, a journal of the Association for Psychological Science, presents a unique longitudinal investigation of depression across four critical developmental periods from childhood to adulthood.
To better understand the developmental course of Major Depressive Disorder (MDD), Paul Rohde of the Oregon Research Institute and colleagues analyzed data collected from individuals participating in the Oregon Adolescent Depression Project.
Using these data, the researchers were able to compare and contrast the presentation of MDD across four developmental periods: childhood (5.0-12.9 years), adolescence (13.0-17.9 years), emerging adulthood (18.0-23.9 years), and adulthood (24.0-30.0 years).
Interviewers assessed participants for symptoms of depression at each of the four time points. The participants also completed follow-up evaluations that assessed the onset and duration of all major psychiatric disorders since the previous time point.
MDD recovery was defined as 8 or more consecutive weeks of no or minor symptoms and MDD recurrence was defined as meeting full MDD criteria following recovery. Both of these definitions are in line with consensus definitions in the field.
The interviewers conducting the diagnostic assessments were carefully selected, trained, and supervised. Each one of the interviewers had a degree in a mental health discipline and had completed a 70-hour course in diagnostic interviewing.
Rohde and colleagues examined data from 816 participants who had completed the questionnaires and interviews at all four time points.
By age 30, 51% of the sample had experienced an episode of MDD. Among the participants who developed one episode of MDD, more than half (53%) had at least one recurrent MDD episode by age 30. Being female was a consistent predictor of a first incidence of MDD in all four of the developmental periods but did not significantly predict recurrence.
First incidence and recurrent episodes of MDD were lower in childhood than in adolescence, emerging adulthood, or adulthood. While MDD during childhood was infrequent, episodes that occurred in this early developmental period lasted significantly longer than those episodes that occurred in the subsequent three periods. As the researchers expected, having an episode in one developmental period was associated with a significantly increased risk of having an episode in subsequent periods.
The researchers found that rates of suicide attempts were significantly higher in adolescents than in either the emerging adult or adult periods, which had similar rates. Among the participants who had a history of MDD through age 30, about 19% had at least one suicide attempt by the fourth time point.
MDD was associated with both anxiety and substance use disorders in all four developmental periods.
The researchers note that, to their knowledge, this is the first study to examine the markers of MDD across these four developmental periods.
Rohde and colleagues argue that this study makes an important contribution to our understanding of how depression emerges and develops over time because it provides critical information about the prevalence, duration, course, patterns of co-occurrence, and longer-term consequences of depression across four markedly diverse developmental periods.
Association for Psychological Science: http://www.psychologicalscience.org
This press release was posted to serve as a topic for discussion. Please comment below. We try our best to only post press releases that are associated with peer reviewed scientific literature. Critical discussions of the research are appreciated. If you need help finding a link to the original article, please contact us on twitter or via e-mail.
Doctors have used perfect replicas of childrens' hearts to uncover and repair hidden defects
An experiment testing people’s altruism in the face of electric shocks is clear on one thing: we are drawn to these little blasts
Researchers gear up tests in West Africa to see whether blood from Ebola survivors can help people who are sick with the disease. This is part of a broader effort to test therapies in West Africa.
The virus's foray into Europe coincides with peak production of Christmas turkeys, the poultry species most vulnerable to bird flu
A novel kind of nanoparticle could lead to more effective cancer treatments.Patients and doctors often don’t know if surgery to remove cancerous tissue was successful until scans are performed months later. A new kind of nanoparticle could show patients if they’re in the clear much earlier.
One challenge in evaluating the effectiveness of different medical procedures, is that patients behave differently after different procedures. Is this true for patients getting heart surgery?
It is only in the aftermath of treatment that survivors discern that their adrenalin alone wont fuel the rest of their recovery. For many, surviving cancer is followed by even more hardship
Just down the road from Facebook and Google, Dr. Phil Wagner runs a laboratory dedicated to optimizing the performance of some of the world's top athletes. At Sparta Performance Science in Menlo Park, California, Wagner and his team bring the spirit of Silicon Valley to bear on the athletic world, helping athletes find the tiny advantages that add to championships. Join us for a trip inside the lab to see where sports meets science.
Pieter Cohen, an internist in Massachusetts, got interested in dietary supplements several years ago, when some of his …
The risk of overdiagnosis and false positives means the UK may be barking up the wrong tree in trialling a wider target age range for breast screening